Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Effects of Metformin in Patients with Poorly Controlled, Insulin-Treated Type 2 Diabetes Mellitus

Bibliographic Data

ID22358377
AuthorsAbid A Altayari (American Pharmacists Association), Khalid Faraj Alrehaili (King Fahad Specialist Hospital), Samar Alharbi (0000-0002-0904-0514, King Fahad Specialist Hospital), Sanad Abdulrahman Alharbi, Yahya Ali Kaabi (King Fahad Specialist Hospital), Abdullah Altamimi (0000-0003-4257-4961, King Fahad Hospital Jeddah), Abdullah Khaled Altamimi, Yousra Khudran Alzahrani (0000-0002-7384-5958, Royal Australian College of General Practitioners), Sabrin Saleh Albalawi (Saad Specialist Hospital), Abdulrahman Soliman Alzeriry (Maternity and Children's Hospital), Abdullah Abdulrahman Saleh Alruwaythi (Security Forces Hospital), Mohammed Yahya M Althubyani (American Pharmacists Association), Mohammed Al Hassan Al Malki, M Malki (American Pharmacists Association), Omar Owaydhah Salem Almotairi (American Pharmacists Association), Muhannad Naffaa Almatrafi (Social Security Office (Thailand))
Year2024
Volume3
Issue8
Publication date2024-12-31
Open AccessYes
TypeARTICLE
VenueJournal of Ecohumanism (JOURNAL)
Journal identifiersISSN: 2752-6798 • E-ISSN: 2752-6801
PublisherCreative Publishing House (PUBLISHER • GB)
DOI10.62754/joe.v3i8.6753
OpenAlexW4410074723
LanguageEN

Background: Metformin is an oral anti-diabetic drug widely recognized as the first-line therapy in the treatment of Type 2 Diabetes Mellitus (T2DM) Aim: To assess the impact of metformin on glycemic control, insulin dosage, and side effects in poorly controlled, insulin-treated type 2 diabetes patients. Patients and methods: A comprehensive literature search was conducted using electronic databases such as PubMed, Embase, Cochrane Library, and Web of Science. The search terms included "metformin," "insulin," "type 2 diabetes," "poorly controlled," and "randomized controlled trial." The search was limited to studies published in English up to December 2022. Results: The study analyzed three studies on total cholesterol levels at follow-up, LDL follow-up, HDL at follow-up, and triglycerides at follow-up. A non-significant heterogeneity was detected, resulting in a non-significant difference between groups. A random-effect model was used for analysis, revealing a combined mean difference of -0.11 and 95% CIs of -2.66. The combined results showed no statistically significant difference between groups regarding LDL baseline (Z = 1.73, P = 0.08), HDL at follow-up (Z = 1.87, P = 0.06), and triglycerides (Z = 1.04, P=0.30). A highly significant heterogeneity was detected in the Side Effect (Two studies reported), demonstrating a highly statistically significant difference between groups regarding this effect (Z = 7.01, P ˂0.001). The results suggest that a combination of factors may influence cholesterol levels and triglycerides at follow-up. Conclusion: Metformin significantly improves diabetes duration, insulin therapy duration, and glycated hemoglobin levels in Type 2 diabetes patients, with moderate side effects risk. Further studies are needed for long-term safety

Diabetes mellitus · Insulin · Metformin · Type 2 diabetes · Type 2 Diabetes Mellitus · Diabetes Management and Research · Diabetes Treatment and Management · Medicine · Metabolism, Diabetes, and Cancer · Endocrinology · Internal Medicine

Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae